

**DAFTAR PUSTAKA**

- Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25676887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet*. 2015; 385: 977–1010.
- Andolf E, Jorgensen C. A prospective comparison of transabdominal and transvaginal ultrasound with surgical findings in gynecologic disease. *J Ultrasound Med* 1990; 9:71–75.
- Bennett, G., Slywotzky, C., & Giovannello, G. (2002). Gynecologic Causes of Acute Pelvic Pain: Spectrum of CT Findings. *Radiographics*, 22(4), 785-801.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* [Internet]. 2018;68(6):394–424. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30207593>
- Chang SJ, Bristow RE, Chi DS, Cliby WA. Role of aggressive surgical cytoreduction in advanced ovarian cancer. *J Gynecol Oncol*. 2015;26(4):336–4].
- Ekerhovd, E., Wienerroith, H., Staudach, A., & Granberg, S. (2001) Preoperative assessment of unilocular adnexal cysts by transvaginal ultrasonography: a comparison between ultrasonographic morphologic imaging and histopathologic diagnosis. *American Journal of Obstetrics & Gynecology*, 184(2), 48–54.
- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer, 2013[2016-09-09]. <http://globocan.iarc.fr>.

- Ferrandina G, Sallustio G, Fagotti A, Vizzielli G, Paglia A, Cucci E, et al. Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: A prospective trial. *Br J Cancer* [Internet]. 2009;101(7):1066–73. Available from: <http://dx.doi.org/10.1038/sj.bjc.6605292>
- Forstner R, Sala E, Kinkel K, Spencer JA. ESUR guidelines: ovarian cancer staging and follow-up. *Eur Radiol*. 2010;20:2773–80.
- M.F. Fathalla, Incessant ovulation and ovarian cancer – a hypothesis re-visited. *FVV in ObGyn*, 2013, 5 (4): 292-297
- Givens, V., Mitchell, G., Smith, C. H., Reddy, A., & Maness, D. (2009). Diagnosis and Management of Adnexal Masses. *American Family Physician*. Retrieved April 12, 2015, from <http://www.aafp.org/afp/2009/1015/p815.html>.
- Granato, T., Midulla, C., Longo, F., Colaprisca, B., Frati, L., & Anastasi, E. (2012). Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. *Tumour Biology*, 33(5), 1335-1339.
- Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, [http://seer.cancer.gov/csr/1975\\_2013/](http://seer.cancer.gov/csr/1975_2013/), based on November 2015 SEER data submission, posted to the SEER website, April 2016.
- Julia Fielding, Douglas Brown, Amy Thurmond, *Gynecological Imaging*. 2011 p 455.
- Jung, S., Lee, J., Rha, S., Byun, J., Jung, J., & Hahn, S. (2002). CT and MR Imaging of Ovarian Tumours with Emphasis on Differential Diagnosis. *Radiographics*, 22(6), 1305-1325.
- Koonings PP, Campbell K, Mishell DR Jr, Grimes DA. Relative frequency of primary ovarian neoplasms: a 10-year review. *Obstet Gynecol* 1989; 74:921–926.

- Kitajima, K., Murakami, K., Yamasaki, E., Kaji, Y., Fukasawa, I., Inaba, N., & Sugimura, K. (2008). Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: Comparison with enhanced CT. *European Journal of Nuclear Medicine and Molecular Imaging*, 35(10), 1912-1920.
- Kinkel K, Lu Y, Mehdizade A, Pelte MF, Hricak H. Indeterminate ovarian mass at US: incremental value of second imaging test for characterization: metaanalysis and Bayesian analysis. *Radiology*. 2005;236:85-94.
- Miller DS, Spirtos NM, Ballon SC, Cox RS, Soriero OM, Teng NN. Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma: minimal diagnostic and therapeutic value in patients with persistent cancer. *Cancer* 1992; 69:502–510.
- M. Meissnitzer; Radiology, University Institute for Radiodiagnostics Salzburg, Salzburg, AUSTRIA).
- NIH Consensus Conference. Ovarian cancer: screening, treatment, and follow-up—NIH Consensus Development Panel on Ovarian Cancer. *JAMA* 1995; 273: 491–497.
- Suppiah S, Kamal SH, Mohd Zabid AZ, Abu Hassan H. Characterization of adnexal masses using multidetector contrast-enhanced CT scan – Recognising common pitfalls that masquerade as ovarian cancer. *Pertanika J Sci Technol*. 2017;25(1):337–52.
- Sahdev A. CT in ovarian cancer staging: How to review and report with emphasis on abdominal and pelvic disease for surgical planning. *Cancer Imaging* [Internet]. 2016;16(1):1–9. Available from: <http://dx.doi.org/10.1186/s40644-016-0076-2>
- Togashi, K. (2003). Ovarian cancer: The Clinical Role of US, CT, and MRI. *European Radiology*, 3(4), L87-104.